Harmony Biosciences Holdings, Inc.

NasdaqGM HRMY

Harmony Biosciences Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 17.98%

Harmony Biosciences Holdings, Inc. Net Income Margin is 17.98% for the Trailing 12 Months (TTM) ending September 30, 2024, a -35.36% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Harmony Biosciences Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 27.82%, a -28.38% change year over year.
Harmony Biosciences Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 38.84%, a 799.89% change year over year.
Harmony Biosciences Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 4.32%, a 106.46% change year over year.
Harmony Biosciences Holdings, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -66.86%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: HRMY

Harmony Biosciences Holdings, Inc.

CEO	Dr. Jeffrey M. Dayno M.D.
IPO Date	Aug. 19, 2020
Location	United States
Headquarters	630 West Germantown Pike
Employees	246
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Key trends

Past 5 years